Get the Stockscreener App
2.775
1.22%
-0.085
After Hours:
2.70
-0.075
-2.70%
Neuraxis Inc stock is traded at $2.775, with a volume of 170.32K.
It is down -1.22% in the last 24 hours and up +20.21% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$2.86
Open:
$2.8
24h Volume:
170.32K
Relative Volume:
0.11
Market Cap:
$24.28M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.4404
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
-6.77%
1M Performance:
+20.21%
6M Performance:
-4.97%
1Y Performance:
-18.12%
1-Day Range:
$2.71
$2.86
1-Week Range:
$2.52
$3.30
52-Week Range:
$1.33
$6.20
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Compare NRXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.775 | 21.86M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Neuraxis Inc Stock (NRXS) Latest News
NeurAxis, Inc. Releases Investor Presentation - TipRanks
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 - The Manila Times
Biotech Alert: Searches spiking for these stocks today - TipRanks
NeurAxis Closes $5 Million Direct Offering - marketscreener.com
NeurAxis, Inc. Completes $5 Million Registered Direct Offering to Support Growth of IB-Stim Therapy - Nasdaq
NeurAxis Announces Closing of $5.0 Million Registered Direct Offering - GlobeNewswire
NeurAxis announces USD 5M registered direct offering - Medical Buyer
NeurAxis, Inc. Announces $5 Million Stock Offering - TipRanks
Form 424B5 Neuraxis, INC - StreetInsider
SEC Form 424B5 filed by Neuraxis Inc. - Quantisnow
Neuraxis settles lawsuit with $750,000 agreement By Investing.com - Investing.com South Africa
NeurAxis, Inc. Receives $1 Million from Warrant Exercises - TipRanks
Neuraxis settles lawsuit with $750,000 agreement - Investing.com
NeurAxis slides 21%, raises $5M via stock - MSN
NeurAxis To Sell About 1.5 Mln Stock At $3.25/shr; Stock Plunges In Pre-market - Nasdaq
NeurAxis (NRXS) Announces $5M Direct Stock Offering - GuruFocus
NeurAxis Launches $5 Million Direct Offering - marketscreener.com
NeurAxis (NRXS) Announces Direct Stock Offering to Raise $5 Mill - GuruFocus
Neuraxis prices 1.54M shares at $3.25 in registered direct offering - TipRanks
NeurAxis Announces $5.0 Million Registered Direct Offering - The Manila Times
Edible Garden's Sports Nutrition Launch On Amazon Sends Stocks Climbing - Finimize
NeurAxis Awarded First Ever FDA Clearance for the Treatment - GlobeNewswire
NeurAxis Stock Soars on Groundbreaking FDA Clearance for Pediatric Treatment - Wall Street Pit
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Wall Street’s Dramatic Shifts Uncover Unexpected Winners and Losers—What’s Behind Today’s Wild Market Moves? - macholevante.com
NeurAxis Shares Climb After FDA Clearance of IB-Stim for Treating Pediatric Dyspepsia - marketscreener.com
NeurAxis (NRXS) Stock Surges Following Breakthrough FDA Clearance - Stocks Telegraph
Neuraxis, Inc. Common Stock (NYSE:NRXS) Stock Quote - FinancialContent
Nasdaq Falls 100 Points; Home Depot Sales Top Views - Benzinga
NRXS stock touches 52-week high of $5.67 amid market fluctuations - Investing.com
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
NeurAxis (NRXS) Gains FDA Clearance for Expanded Use of IB-Stim - GuruFocus
Neuraxis Awarded First Ever FDA Clearance For The Treatment Of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms - marketscreener.com
Neuraxis awarded FDA clearance for treatment of pediatric FAP, FD symptoms - TipRanks
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms - Yahoo Finance
NeurAxis Stock Gains Following Strong Q1 Earnings and FDA Milestones - MSN
NeurAxis Stock Gains Following Strong Q1 Earnings And FDA Milestones - Barchart.com
NeurAxis (NRXS) Sees Q1 Revenue Surge; Eyes Future Growth Opport - GuruFocus
NeurAxis, Inc. Reports Increased Sales Amidst Losses - TipRanks
NeurAxis Earnings Call: Growth Amid Challenges - TipRanks
Transcript : NeurAxis, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Earnings call transcript: Neuraxis sees 39% revenue boost in Q1 2025 - Investing.com Nigeria
NeurAxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Neuraxis reports Q1 EPS (33c) vs. (32c) last year - TipRanks
NeurAxis, Inc. Reports 39% Revenue Growth in Q1 2025 Amid Expansion of Neuromodulation Therapies - Nasdaq
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues - GlobeNewswire
Vagus Nerve Stimulators Market Is Booming Worldwide | LivaNova - openPR.com
Crude Oil : How we spotted the direction based on Elliott Wave - The Globe and Mail
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025 - The Manila Times
350 Million Reasons to Buy Meta Platforms Stock After Q1 Earnings - The Globe and Mail
The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis - Yahoo Finance
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.89%
3.67%
Cap:
|
Volume (24h):